Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Williams: Disorders of Carbohydrates and Fat Metabolism > III. Therapeutics of Type 2 Diabetes Mellitus > Flashcards

III. Therapeutics of Type 2 Diabetes Mellitus Flashcards

1
Q

The risk of heart disease and stroke is commonly stated to be ___ times higher for people with diabetes than for those without diabetes.

A

2-4 times

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Lower-extremity amputation is approximately ___ times higher for people with diabetes than for those without diabetes.

A

20 times

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Life expectancy is reduced by approximately ___ years in people with diabetes.

A

10 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

The hazard ratio for death is most pronounced in those having diabetes under ___ years.

A

55 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Convert mmol/L to mg/dL by ___

A

Multiply by 18

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Fasting plasma glucose in mg/L that is diagnostic for prediabetes and diabetes (no calorie intake at least 8 hours)

A

100-125
>=126

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

2-hour plasma glucose in mg/L that is diagnostic for prediabetes and diabetes (after 75g oral glucose)

A

140-199
>=200

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Random plasma glucose in mg/L that is diagnostic for diabetes (with classic symptoms)

A

> =200

(not applicable for prediabetes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

HbA1c that is diagnostic for prediabetes and diabetes

A

5.7-6.4%
>=6.5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

TRUE or FALSE: Diagnosis of diabetes should be confirmed by repeat testing.

A

TRUE, in the absence of unequivocal hyperglycemia

A confirmatory test by the same or a different method is usually required to confirm the diagnosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

The primary endpoint used to evaluate the relationship between glucose levels and complications

A

Retinopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Not recommended for routine use in diagnosing diabetes
a. Fasting plasma glucose
b. 2-hour plasma glucose (OGTT)
c. Random plasma glucose
d. HbA1c

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

People with undiagnosed T2DM have approximately ___fold greater risk for coronary heart disease, stroke, and peripheral vascular disease.

A

Twofold

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Who among the following should be tested for diabetes (ADA 2018)? (all that applies)
a. 44/M, Asian, BMI 22, with active lifestyle
b. 32/F, Asian, BMI 24, active lifestyle
c. 24/F, Asian, BMI 22, with PCOS
d. 50/M, Caucasian, BMI 19, with no comorbidity
e. 28/F, Asian, BMI 18, with history of GDM lost to follow-up

A

A, B, D, and E

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

4 Populations that should be tested for prediabetes

A
  1. Overweight or obese (BMI >=25 or >=23 in Asians) + 1 or more risk factor
  2. Patients with prediabetes (yearly)
  3. Patients with prior GDM (at least every 3 years)
  4. All others - begin at age 45 (begin at age 35 based on ADA 2022)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Risk factors that, if present in an overweight/obese person, should prompt testing for prediabetes

A

General profile:
1. High-risk ethnicity (e.g., African, Latino, Native American, Asian, Pacific Islander)

Past Medical History:
1. History of cardiovascular disease
2. Hypertension (BP >=140/90 or using BP-lowering therapy)
3. PCOS

Personal/Social History:
1. Physical inactivity

Family History:
1. First-degree relatives with diabetes

Objective:
1. Severe obesity
2. Acanthosis nigricans
3. HDL <35 mg/dL and/or triglycerides >250 mg/dL

*Other conditions associated with insulin resistance (e.g., severe obesity, acanthosis nigricans)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Level of HDL and triglycerides considered a risk factor for prediabetes in asymptomatic adults

A

HDL <35 mg/dL and/or triglycerides >250 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Frequency of testing for asymptomatic adults with prediabetes

A

Yearly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Frequency of testing for asymptomatic adults with history of gestational diabetes

A

At least every 3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Age at which to start testing for prediabetes in asymptomatic adults (if without other risk factor)

A

45 years old (35 based on ADA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

If initial results for testing for prediabetes are normal, when to repeat?

A

At least every 3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the United Kingdom Prospective Diabetes Study (UKPDS)?

A

Prospective, randomized trial that documented reduced rates of microvascular complications in T2DM patients treated to lower glycemic targets and with pharmacotherapy compared to lifestyle alone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Treatment effect of sulfonylurea or insulin in the UKPDS (% relative risk reduction and if significant) at end of randomized treatment
a. Any diabetes-related endpoint
b. Microvascular disease
c. Myocardial infarction
d. All-cause mortality

A

a. Any diabetes-related endpoint - 12% (significant)
b. Microvascular disease - 25% (significant)
c. Myocardial infarction - 16% (NS)
d. All-cause mortality - 6% (NS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Treatment effect of sulfonylurea or insulin in the UKPDS (% relative risk reduction and if significant) after 10 years of further observation
a. Any diabetes-related endpoint
b. Microvascular disease
c. Myocardial infarction
d. All-cause mortality

A

a. Any diabetes-related endpoint - 9% (significant)
b. Microvascular disease - 24% (significant)
c. Myocardial infarction - 15% (significant)
d. All-cause mortality - 13% (significant)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Treatment effect of metformin in the UKPDS (% relative risk reduction and if significant) at end of randomized treatment
a. Any diabetes-related endpoint
b. Microvascular disease
c. Myocardial infarction
d. All-cause mortality

A

a. Any diabetes-related endpoint - 32% (significant)
b. Microvascular disease - 29% (NS)
c. Myocardial infarction - 39% (significant)
d. All-cause mortality - 36% (significant)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Treatment effect of metformin the UKPDS (% relative risk reduction and if significant) after 10 years of further observation
a. Any diabetes-related endpoint
b. Microvascular disease
c. Myocardial infarction
d. All-cause mortality

A

a. Any diabetes-related endpoint - 21% (significant)
b. Microvascular disease - 16% (NS)
c. Myocardial infarction - 33% (significant)
d. All-cause mortality - 27% (significant)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

This “effect” is believed to be responsible for the persistence of the relative benefits of more intensive management of glucose after 10 more years of observation in the UKPDS (even though the difference in glycemic control was not maintained)

A

“Legacy effect” of initially good glycemic control, likely based on persisting changes of tissue structure in blood vessels and elsewhere

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Kumamoto study results

A

Japanese patients with T2DM with normal weight randomized into standard or intensive treatment with insulin –> Lower HbA1c with modestly increased risk of hypoglycemia and weight gain, reduction in microvascular complications, and a (not statistically significant) trend toward reduced rates of cardiovascular events

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

TRUE or FALSE: The Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and Vascular Disease - Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE), and the Veterans Affairs Diabetes Trial (VADT) - which randomized middle-aged and older individuals into standard and intensive treatment - all demonstrated significant benefit in combined cardiovascular endpoints.

A

FALSE

None of the trials demonstrated significant benefit in combined cardiovascular endpoints.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

The ACCORD study showed that a __% increase in total mortality accompanied intensive therapy.

A

22%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

ADA target preprandial plasma glucose

A

80-130 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

ADA target peak postprandial plasma glucose

A

<180 mg/dL (1 to 2 hours after any meal)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

ADA target mean plasma glucose

A

<154 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

ADA target HbA1c

A

<7%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

ADA - may pursue lower target HbA1c in ___

A

Those with recent-onset disease, long life expectancy, and no significant cardiovascular disease, if they can be achieved without significant hypoglycemia or other adverse effects of treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

ADA - may pursue less stringent HbA1c at 7-8% in ___

A

Those at high risk, including a history of severe hypoglycemia, limited life expectancy, advanced complications, or extensive comorbid conditions, as well as inability to achieve HbA1c less than 7% despite the usual initial therapeutic efforts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

ACE target fasting glucose

A

<110 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

ACE target 2-hour postprandial glucose

A

<140 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

ACE target HbA1c

A

<6.5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Frequency of HbA1c monitoring

A

When treatment is started or intensified, measurement at approximately 3-month intervals will reveal the success of the intervention.

When treatment is established and glycemic control appears stable, testing one or two times a year is usually sufficient.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Term used to refer to the mismatch between glucose and HbA1c levels

A

Glycation cap

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Increased red cell turnover such as in occult blood loss or iron treatment of iron deficiency anemia could lead to a ___ HbA1c

A

Lower

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Low red cell turnover such as in untreated iron deficiency anemia could lead to a ___ HbA1c

A

Higher

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Use of self-monitoring of blood glucose is particularly recommended for patients with T2DM who are taking ___

A

Insulin or sulfonylureas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

TRUE or FALSE: One basic principle is that patients should test blood glucose at the same time each day.

A

FALSE

One basic principle is that patients should periodically vary the time of day at which glucose is tested.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Finding of the Structured Testing Program (STeP) trial

A

Use of 7-point daily glucose testing for 3 days each quarter increased the frequency of treatment adjustments and improved HbA1c levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Criteria for ADA Level 1 Hypoglycemia (Alert value)

A

Blood glucose <70 mg/dL and >=54 mg/dL

Triggers physiologic responses of the so-called counterregulatory hormones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Criteria for ADA Level 2 Hypoglycemia (Clinically significant)

A

Blood glucose <=54 mg/dL

Can cause blunting of compensatory hormone responses and loss of warning symptoms (“hypoglycemia unawareness”)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Criteria for ADA Level 3 Hypoglycemia (Severe)

A

Altered mental and/or physical status requiring assistance

Strongly associated with risk of physical injury, cardiovascular events, and death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Diabetes self-management education and support (DSMES) is recommended to be emphasized at these 4 critical settings in the evolution of T2DM

A
  1. At diagnosis
  2. Annual assessment
  3. When complicating factors arise
  4. When critical transitions in medical care occur or life circumstances
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Recent guidelines recommend ___ MNT sessions in the first 6 months after diagnosis

A

3-6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Medical nutrition therapy has been shown to decrease HbA1c by __ to __%.

A

0.3% to 2%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Achieving a __% weight loss more consistently yields significant metabolic benefits than lower levels of weight loss, and benefits obese and overweight prediabetic and diabetic patients.

A

5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

In general, the critical nutrient for glycemic consistency

A

Carbohydrate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

TRUE or FALSE: Whereas the beta cell in T2DM has usually lost its immediate response to glucose, the second phase of insulin secretion is largely spared in T2DM and is in part driven by amino acids and fatty acids.

A

TRUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

TRUE or FALSE: There is no single ideal dietary distribution of calories among macronutrients.

A

TRUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

What is the glycemic index?

A

The glycemic index refers to the glucose response to equal amounts of carbohydrates in various foods.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Nutrient that is most closely associated in epidemiologic studies with the risk of developing T2DM

A

Fat (but has little effect on glycemia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Critical nutrient for cardiovascular risk management

A

Fat

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

TRUE or FALSE: Dietary protein has little impact on glucose levels.

A

TRUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

TRUE or FALSE: Metabolism of protein results in the formation of acids and nitrogenous waste, which can lead to bone demineralization and glomerular hyperfiltration.

A

TRUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

At least ___g of high-quality dietary protein per kilogram of body weight is generally recommended.

A

0.8g

Recent guidelines do not support the notion that dietary protein need to be reduced in those with CKD.
No evidence for a distinction between the effects of vegetable-based versus animal-based protein sources in kidney function.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Restriction of protein intake to __ to __% of total calories minimizes potential adverse long-term effects of high protein intake.

A

10 to 20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Carbohydrate sources high in ___ should be avoided when trying to treat or prevent hypoglycemia.

A

Proteins

Ingested protein appears to increase insulin response without increasing plasma glucose concentrations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Eating foods rich in ___, such as fatty fish (EPA and DHA) and nuts and seeds (ALA), is recommended to prevent or treat CVD.

A

Long-chain n-3 fatty acids

(However, evidence does not support a beneficial role for routine use of n-3 dietary supplements.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

Eating foods rich in long-chain n-3 fatty acids, such as fatty fish (EPA and DHA) and nuts and seeds (ALA), is recommended to prevent or treat ___.

A

CVD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

TRUE or FALSE: Micronutrients and herbal supplements have proven benefit and are generally recommended in T2DM patients.

A

FALSE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

There may be some benefit on HbA1c and lipid profiles for those ingesting at least __g of fiber per 1000kcal compared to lower fiber diets.

A

15g

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

TRUE or FALSE: Alcohol in moderation (up to 1 drink per day for adult women or 2 drinks per day in adult men) is not specifically recommended.

A

TRUE

..but is considered acceptable.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

Risk of excessive intake of alcohol by people with T2DM, especially those who use sulfonylureas or insulin

A

Delayed hypoglycemia, which typically occurs at night when ability to recognize hypoglycemia is impaired

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

TRUE or FALSE: Moderate red wine intake may result in mild improvement in some lipid parameters but seems to have little effect on glucose control.

A

TRUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

TRUE or FALSE: Nonnutritive sweeteners do not appear to impact lipid parameters, insulin secretion, or blood pressure independent of weight loss, and are deemed safe in any amount.

A

FALSE

Deemed safe for use in T2DM if consumed within the FDA recommended daily intake amounts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

Recommended sodium restriction in patients with diabetes

A

Less than 2300 mg per day (as with the general population, but those with hypertension may have additional benefit from lower sodium diets)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

TRUE or FALSE: Ketogenic diets or low carbohydrate diets have evidence of long-term benefit in patients with diabetes.

A

FALSE

Limited long-term evidence of benefit or risk at the present time.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

3 most validated meal plans in T2DM

A
  1. Mediterranean diet
  2. Dietary Approaches to Stop Hypertension (DASH)
  3. Plant-based diets
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

Meal plan that has the best experiment support for glycemic control, cardiovascular protection, and perhaps other outcomes

A

Mediterranean diet (emphasizing the use of monounsaturated and polyunsaturated fats)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Self-directed structured exercise programs have been associated with mean HbA1c reductions of __ to __%.

A

0.4 to 0.9%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

After exercise, improvements in glycemic control are usually apparent immediately, but the improvement in insulin resistance may not last more than __ to __ hours.

A

48 to 72 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

Recommended duration of physical activity

A

150 minutes of moderate-intensity physical activity (50-70% of maximum heart rate) or 75 minutes of vigorous exercise (>70% of maximum heart rate) on at least 3 days per week, with no more than 2 consecutive days without exercise

*Max heart rate = 220 - age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

Recommended type of physical activity

A

Both aerobic and resistance exercise are effective and recommended.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

Major role for the physician in terms of physical activity of patients with T2DM

A

The major role for the physician is to screen for complications (neuropathy, nephropathy, retinopathy, vascular disease) and discover ways for patients to be able to exercise safely.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

For the average patients with T2DM starting an exercise program it is best to start with ___-level activity such as ___ at a pace of ___.

A

Low-level
Walking
2 miles per hour

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

TRUE or FALSE: Exercise can increase albuminuria acutely.

A

TRUE

Exercise does not appear to accelerate kidney disease but will increase albuminuria acutely and could cause false-positive albumin:creatinine ratios temporarily.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

Recommended frequency of activity break in all individuals

A

At least every 30 minutes, to include brief walks, resistance exercise, or at least standing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

Recommended frequency for screening for diabetes distress

A

At least once yearly, as depression is present in about 25% of screened patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

Mechanism of effect on glucose of biguanide

A

Decrease hepatic glucose production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

Mechanism of effect on glucose of secretagogue

A

Increase insulin secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

Mechanism of effect on glucose of thiazolidinedione

A

Decrease insulin resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

Mechanism of effect on glucose of DPP4 inhibitor

A

Increase insulin, decrease glucagon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

Mechanism of effect on glucose of alpha-glucosidase inhibitor

A

Delay carbohydrate absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

Mechanism of effect on glucose of SGLT inhibitor

A

Increase renal clearance of glucose, sodium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

Mechanism of effect on glucose of bile acid sequestrant

A

Delay carbohydrate absorption?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
93
Q

Mechanism of effect on glucose of dopamine agonist

A

Decrease insulin resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
94
Q

Mechanism of effect on glucose of insulin

A

Increase insulin availability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
95
Q

Mechanism of effect on glucose of GLP1 receptor agonist

A

Increase insulin, decrease glucagon, slow gastric emptying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
96
Q

Mechanism of effect on glucose of amylin receptor agonist

A

Decrease glucagon, slow gastric emptying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
97
Q

Which classes of agents have +++ basal glucose control?

A

Insulin
Secretagogue
Biguanide
Thiazolidinedione
GLP1 receptor agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
98
Q

Which classes of agents have +++ prandial glucose control?

A

Insulin
GLP1 receptor agonist
Alpha-glucosidase inhibitor
Amylin receptor agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
99
Q

Which classes of agents have +++ weight control?

A

SGLT inhibitor
GLP1 receptor agonist
Amylin receptor agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
100
Q

Which classes of agents cause weight increase?

A

Insulin
Secretagogue
Thiazolidinedione

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
101
Q

Which classes of agents have no effect on weight?

A

DPP4 inhibitor
Bile-acid sequestrant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
102
Q

Which classes of agents have ++ BP control?

A

SGLT inhibitor
GLP1 receptor agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
103
Q

Which classes of agents have +++ short-term CV reduction?

A

SGLT inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
104
Q

*Table 35.10 Classes of antihyperglycemic agents for type 2 diabetes. Page 1385

A

*

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
105
Q

Most common adverse events of biguanides

A

Gastrointestinal: nausea, abdominal pain or bloating, and diarrhea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
106
Q

Advantage of using sustained-release metformin

A

Less frequent and less severe upper GI symptoms, but can increase the frequency of diarrhea, which is overall less common

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
107
Q

TRUE or FALSE: Lactic acidosis from metformin is common.

A

FALSE

Metformin has been said to cause lactic acidosis, which is quite rate and occurs almost exclusively in patients who are at high risk for development of the condition independent of metformin therapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
108
Q

Route of metabolism and clearance of metformin

A

Metformin is not metabolized and is cleared only through the kidney.

109
Q

Recommended eGFR monitoring if metformin is to be given

A

Obtain an eGFR before starting metformin and at least annually thereafter

110
Q

Treatment decisions regarding metformin if eGFR is below 45 mL/min/1.73m2

A

Initiation is not recommended;
If treatment is established, consider dose reduction

111
Q

Treatment decisions regarding metformin if eGFR is below 30 mL/min/1.73m2

A

Initiation is contraindicated;
If treatment is established, metformin should be stopped

112
Q

Contraindications for metformin use

A

Hepatic insufficiency
Alcohol abuse
eGFR <30 mL/min/1.73m2

113
Q

Vitamin supplementation for patients using metformin

A

Supplementation with vitamin B 12(e.g., 1000 mcg daily) or intermittent monitoring may sometimes be prudent.

114
Q

Maximal daily dose of metformin

A

2550 mg

But does not generally provide additional benefit beyond that seen at 2000 mg daily

115
Q

Drug class that arguably has the best record among oral antihyperglycemic agents in medical outcome studies

A

Metformin

116
Q

Drug that is generally recommended to be started in all patients with T2DM at or near the time of diagnosis of diabetes, provided no contraindications are present

A

Metformin

117
Q

Currently available secretagogues all bind to the ___ receptor

A

SUR1, subunit of K ATP potassium channel on the plasma membrane of pancreatic beta cells

118
Q

TRUE or FALSE: The effect of secretagogues on insulin secretion wane on subsequent doses.

A

TRUE

A direct effect on insulin secretion, independent of ambient glucose levels, is seen with the first dose of any secretagogue. However, this direct effect wanes during continued occupancy of SUR1, while potentiation of the effect of current glucose levels continues.

119
Q

Classes of secretagogues

A

Sulfonylureas
Non-sulfonylureas: Meglitinides, Nateglinides

120
Q

Differentiate the secretagogues in terms of risk of hypoglycemia, effect on postprandial glucose, and effect on fasting glucose

A

Long-acting Sulfonylureas (glipizide-ER, glimepiride, gliclazide-MR) - Lower fasting glucose levels with little effect on postprandial glucose levels, and relatively low risk of hypoglycemia compared with other secretagogues

Shorter-acting Sulfonylureas (glipizide, glyburide, gliclazide) - As effective as longer-acting agents in overall glucose control, but have greater effect on postprandial hyperglycemia and can cause daytime hypoglycemia when food intake is reduced

Meglitinides (repaglinide) - Have faster and briefer stimulus to insulin secretion than short-acting sulfonylureas, hence better postprandial control and generally less hypoglycemia, but has long residence time on SUR1 and therefore some effect on fasting glucose

Nateglinide - Quicker onset and shorter duration of action than repaglinide, hence, its effect in lowering postprandial glucose is quite specific, and has little effect on fasting glucose, and less overnight hypoglycemia. Disadvantage is less overall glucose-lowering effectiveness

121
Q

Long-acting sulfonylurea that is cleared only by the kidney and thus can cause severe hypoglycemia when renal function becomes impaired

A

Chlorpropamide

None of the other agents is strongly dependent on renal excretion

122
Q

Short-acting sulfonylurea that has an active metabolite that can be cleared only by the kidney

A

Glyburide (hence associated with greater risk of hypoglycemia than other currently used sulfonylureas)

123
Q

Reason for the concern that sulfonylureas might cause increased arrhythmic cardiovascular events in patients with diabetes

A

They have an effect on SUR2 subunits of the K ATP complex in vascular and cardiac cells. Binding to SUR2 can blunt ischemic preconditioning, a normal cardioprotective mechanism.

124
Q

TRUE or FALSE: The ADVANCE trial did not show any evidence of cardiovascular toxicity with sulfonylureas.

What drug was used as its dominant glucose-lowering strategy?

A

TRUE

Extended-release gliclazide (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation)

125
Q

TRUE or FALSE: The UKPDS demonstrated long-term safety relative to lifestyle intervention for glyburide, glipizide, and chlorpropamide. (with emphasis on cardiovascular toxicity)

A

TRUE

126
Q

The adverse effect of increased arrhythmic cardiovascular events has been confirmed with these sulfonylureas

A

Tolbutamide and glyburide (especially relevant to glyburide)

127
Q

The maximum approved dose for the sulfonylureas is __ to __ times higher than the maximum effective dose.

A

Two to four times

128
Q

Initiating treatment with no more than a ____ of the maximal approved dose provides significant glucose lowering while limiting costs and adverse events.

A

Quarter

Small doses of the longer-acting modern sulfonylureas (e.g., 0.5-1 mg of glimepiride or 2.5 mg of extended-release glipizide) are often effective, particularly in patients receiving metformin concomitantly, and are almost always well tolerated.

129
Q

Leading disadvantages of sulfonylureas

A

Tendency to cause hypoglycemia and usually modest weight gain

130
Q

Maximum dose of repaglinide

A

4 mg with each meal

131
Q

Rationale of using non-sulfonylureas, and probable reason why they are still only modestly used

A

They stimulate insulin secretion at mealtime to improve postprandial control without increasing the risk of overnight hypoglycemia. They also demonstrate little binding to the vascular smooth muscle and cardiac SUR2 receptors.

However, there is need for multiple daily doses, higher cost than sulfonylureas, and lack of head-to-head comparative studies that demonstrate superiority over the newer sulfonylureas.

132
Q

Mechanism of thiazolidinediones (pioglitazone and rosiglitazone)

A

Bind to and modulate the activity of a family of nuclear transcription factors termed peroxisome proliferator-activated receptors (PPARs). They are associated with slow improvement in glycemic control over weeks to months in parallel with an improvement in insulin sensitivity and a reduction in free fatty acid levels.

133
Q

Recommended tests prior to beginning TZD therapy

A

Liver function tests

Consider assessment of risk factors and measurement of bone density before prescribing a TZD, especially for women

134
Q

Contraindications for TZDs

A

Active hepatocellular disease
Unexplained serum ALT levels greater than 2.5 times the upper limit of normal

135
Q

TRUE or FALSE: No substantial evidence has linked the newer TZDs to hepatotoxicity.

A

TRUE

(Nonetheless, recent studies show a favorable effect of pioglitazone on nonalcoholic steatohepatitis, a common an otherwise difficult to treat condition.)

136
Q

Compare the effects of the TZDs to triglyceride, HDL, and LDL levels

A

Pioglitazone
- Reduced triglycerides by approx 20%
- Modestly greater improvement in HDL particle number and size
- Improvement in LDL particle size and number

Rosiglitazone
- Increased triglycerides on average by 5%
- Increase in LDL particle number and improved LDL particle size

137
Q

What is the PROactive Study

A

PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) Study

Randomized, double-blind, placebo-controlled trial comparing placebo vs 45 mg pioglitazone

Primary endpoint: Time from randomization to macrovascular outcomes –> No significant improvement with pioglitazone

Secondary endpoint: Cardiovascular composite endpoint –> Marginally significant 16% reduction

138
Q

What is the RECORD Trial

A

Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD) Trial

Compared effect of adding rosiglitazone vs either metformin or SU to patients who had T2DM inadequately controlled with SU or metformin –> No difference in cardiovascular hospitalizations or death

139
Q

What is ADOPT

A

A Diabetes Outcome Progression Trial

Found that patients with early diabetes had a slower rate of secondary glycemic failure when they were treated with rosiglitazone compared with metformin and glyburide

140
Q

Adverse effects and concerns with use of TZDs (5)

A

Weight gain
Fluid retention
Increased risk of bone fractures
Anemia
Bladder cancer

141
Q

Cause of weight gain during use of TZDs

A

The weight gain has been shown to result both from extracellular fluid accumulation and an increase in subcutaneous but not visceral fat.

142
Q

Patients most likely to experience edema while using TZDs

A

Those using insulin and those with preexisting edema

143
Q

Recommendation to patients using TZDs who develop 1) Weight accompanied by increasing edema, 2) Clinically apparent heart failure

A

1) Restrict sodium intake, start a diuretic, or to increase their diuretic dosage as needed

Many patients with mild edema respond to a thiazide diuretic or spironolactone, and combination therapy with a moderate-dose loop diuretic may be considered.

2) Discontinue TZD

144
Q

Initial and highest approved dose of pioglitazone

A

Usually prudent to begin therapy with lowest available dose of 15mg daily. May increase to 30mg after 3 months if inadequate glycemic response and no significant edema. Highest approved dose of 45mg is less well tolerated.

145
Q

Regarding bone fractures with TZD use - gender and age mainly affected, and sites primarily affected

A

Older women
Distal sites

146
Q

Mechanism of increased bone fractures in TZDs

A

Preclinical studies suggest that activation of PPAR gamma inhibits bone formation by diverting stem cells from the osteogenic to the adipocytic lineage.

147
Q

TRUE or FALSE: Pioglitazone has a confirmed association with bladder cancer.

A

FALSE

Large, long-term studies have not confirmed this association. However, current recommendations to avoid its use in patients with a history of bladder cancer seem prudent (due to inconsistent preclinical and clinical observations).

148
Q

TRUE or FALSE: Oral glucose has a greater stimulatory effect on insulin secretion than does intravenous glucose at the same circulating glucose concentration.

A

TRUE

149
Q

Cells that secrete GLP1

A

Intestinal L cells

150
Q

Duration before secreted GLP is inactivated in plasma by enzyme dipeptidyl peptidase-4

A

Very rapidly (1-2 minutes)

151
Q

DPP4 inhibitors increase fasting and postprandial levels of GLP1 about __fold.

A

Twofold

152
Q

TRUE or FALSE: DPP4 inhibitors elevate GLP1 and potentiate glucose-dependent insulin secretion, suppresses basal and postprandial glucagon, improves satiety, and slows gastric emptying.

A

Elevation of GLP1 potentiates glucose-dependent insulin secretion and suppresses basal and postprandial glucagon. However, NEITHER satiety NOR the rate of gastric emptying is affected.

153
Q

Main clinical effect of DPP4 inhibitors

A

Lower fasting glucose levels

154
Q

Reduction of HbA1c with use of DPP4i

A

0.5 to 1%

Relatively weak glucose-lowering power that is partly dependent on retained beta-cell function

155
Q

TRUE or FALSE: DPP4i have no consistent effect on weight and no tendency to cause hypoglycemia when used alone or with metformin.

A

TRUE

156
Q

Contraindication for DPP4i use

A

Prior history of pancreatitis

157
Q

DPP4i that has shown increased risk for heart failure hospitalizations in cardiovascular outcome trials.

A

Saxagliptin

158
Q

DPP4i in current use are partially cleared by the kidney, the usual dose is the maximum marketed dose, and smaller doses are recommended in the setting of stage 3 or greater CKD, except ___.

A

Linagliptin

159
Q

Mechanism of action of alpha-glucosidase inhibitors (acarbose, miglitol, voglibose)

A

Slow the terminal step of carbohydrate digestion at the brush border of the intestinal epithelium, hence carbohydrate absorption is shifted more distally in the intestine and is delayed, allowing the sluggish insulin secretory dynamics characteristic of T2DM to catch up with carbohydrate absorption

160
Q

Regarding alpha-glucosidase inhibitors (acarbose, miglitol, voglibose) - timing of administration, common side effect, and intensity of blood glucose reduction

A

At beginning of each meal
Flatulence (also diarrhea, abdominal discomfort)
Modest reduction in blood glucose level

161
Q

TRUE or FALSE: Some evidence suggest that acarbose improves cardiovascular outcomes better than most antihyperglycemic agents.

A

TRUE

162
Q

Under normal conditions about ___g of glucose is filtered from plasma at the glomerulus and reabsorbed in the ___ tubule

A

180g
Proximal tubule

163
Q

Differentiate SGLT2 and SGLT1 with regards to capacity, affinity, and percentage of renal tubular glucose reabsorbed

A

SGLT2 - high-capacity, low-affinity, responsible for 90%

SGLT1 - low-capacity, high-affinity, responsible for 10% (but critically important for glucose absorption from the gut)

164
Q

TRUE or FALSE: SGLT2 inhibitors reduce both fasting and postprandial glucose levels and promote modest weight loss through loss of calories as glucosuria.

A

TRUE

165
Q

TRUE or FALSE: SGLT2 inhibitors have no effect on blood pressure.

A

FALSE

They also reduce blood pressure, at least in part by increasing sodium clearance and reducing extracellular gluid volume.

166
Q

TRUE or FALSE: All SGLT2i are relatively specific for inhibiting SGLT2.

A

TRUE

But others in development also have some effect on SGLT1

167
Q

In 26-week studies, SGLT2i lead to approximately __ to __kg more weight loss than placebo.

A

2 to 3 kg

168
Q

What is the EMPA-REG OUTCOME trial?

A

Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients - Removing Excess Glucose trial

Empagliflozin - 32% relative risk reduction of all-cause mortality, 38% reduction of CV mortality, and 35% reduction of hospitalization for heart failure

169
Q

What is the CANVAS program?

A

CANagliflozin cardioVascular Assessment Study

Canagliflozin - generally similar effects as EMPA-REG, although quantitatively less prominent, cardiovascular and renal results

170
Q

Most common side effects of SGLT2i

A

Urinary frequency, genital infections, and relatively rare episodes of lower UTIs as well as dehydration and its consequences

171
Q

Regarding genital infections in SGLT2i use - gender more commonly affected, and type of microbe commonly related

A

10-15% of women (about a fivefold increase of risk)
Yeast
May recur

In males - genital mycotic infections are much less common and predominantly found in those who have not been circumcised

172
Q

SGLT2i associated with increased lower extremity amputations in a cardiovascular outcome trial

A

Canagliflozin (CANVAS?)

173
Q

TRUE or FALSE: Good renal function is not essential for full efficacy of SGLT2 inhibitors.

A

FALSE

Good renal function IS essential for full efficacy of SGLT2 inhibitors.

174
Q

Initiation of SGLT2 is not recommended, or if already in use, should be discontinued when eGFR is below ___.

A

45 ml/min/1.73m2

175
Q

The only SGLT2 with a warning against use in patients with bladder cancer.

A

Dapagliflozin

176
Q

Possible mechanisms of euglycemic DKA in T2DM patients on SGLT2i

A

Tendency toward dehydration, elevation of circulating glucagon levels, and accelerated gluconeogenesis due to glucosuria during fasting

177
Q

Second-generation bile acid sequestrant that has been observed to mediate modest reductions in glucose during the clinical development program

A

Colesevelam

178
Q

HbA1c reduction with use of colesevelam

A

0.5% (on table: 0.5 to 1%)

179
Q

Effects of colesevelam on lipid parameters

A

Approximately 15% improvement in LDL. HDL changes tent to be trivial. Triglycerides can increase by 5-20%. (Correlate with rosiglitazone)

180
Q

Basis for use of bromocriptine in T2DM

A

It is suggested that creating a circadian peak in central dopaminergic tone improves insulin sensitivity

181
Q

Timing of administration of quick-release formulation of bromocriptine for T2DM

A

Within 2 hours of rising in the morning

182
Q

HbA1c reduction with use of bromocriptine

A

As high as 1.2% (on table - 0.5 to 1%)

183
Q

TRUE or FALSE: In a 1-year safety study, bromocriptine has shown that broad cardiovascular outcomes were improved 40% compared with placebo.

A

TRUE

184
Q

TRUE or FALSE: Based on Table 35.11, T1D and DKA are contraindications to all commonly used OHAs

A

TRUE

185
Q

HbA1c reduction with use of metformin

A

1 to 2%

186
Q

HbA1c reduction with use of secretagogues

A

1 to 2%

187
Q

HbA1c reduction with use of TZDs

A

0.75 to 1.5%

188
Q

Side effect of DPP4i

A

Hypersensitivity

189
Q

Side effects of SGLT2i aside from urinary frequency and urogenital infections

A

Nausea, diarrhea, hypotension

190
Q

HbA1c reduction with use of alpha-glucosidase inhibitors

A

0.5 to 1%

191
Q

HbA1c reduction with use of SGLT2i

A

0.5 to 1%

192
Q

OHAs with 1 to 2% HbA1c reduction as first or second therapy (2)

A

Metformin
Secretagogues

193
Q

OHAs with 0.75 to 1.5% HbA1c reduction as first or second therapy (1)

A

Thiazolidinediones

194
Q

OHAs with 0.5 to 1% HbA1c reduction as first or second therapy (5)

A

DPP4i
AGI
SGLT2i
Colesevelam
Bromocriptine

195
Q

Side effects of bromocriptine

A

Somnolence, dizziness, hypotension

196
Q

Most common adverse effect of bromocriptine, occurring in about 30% of patients and leading to discontinuation in about 10% at highest doses.

A

Nausea

197
Q

Side effect of colesevelam

A

Constipation

198
Q

Table 35.13 Clinical Features of Commonly Used Insulins, page 1392

A

*

199
Q

Molecular basis of longer action of insulin detemir

A

Fatty acid side chain is covalently bound to the insulin molecule, resulting in slowing of both absorption from subcutaneous tissue and clearance from circulation

200
Q

TRUE or FALSE: Detemir’s time of onset and duration of action are longer than that of NPH.

A

FALSE

Detemir’s time of onset and duration of action are quite similar to those of NPH, but more consistent from injection to injection.

201
Q

Molecular basis of longer action of insulin glargine

A

Soluble at acid pH but precipitates when neutralized in tissues after injection

202
Q

Cause for longer action of insulin degludec and insulin glargine 300

A

Insulin degludec - due both to slower absorption after injection and to delayed clearance

Insulin glargine 300 units/mL - results entirely from an effect on absorption

203
Q

TRUE or FALSE: Regular human insulin administered intravenously is immediately effective, with a half-life on the order of 30 minutes.

A

FALSE

Regular human insulin administered intravenously is immediately effective, with a half-life on the order of 10 minutes.

Lispro, aspart, and glulisine are approved in the US for intravenous use but offer no advantage over regular insulin for this purpose and cost much more.

204
Q

Peak activity of inhaled human insulin (Afrezza)

A

In 30 minutes (the tmax is about 10 minutes), much earlier than lispro

205
Q

Required testing prior and during use of inhaled insulin

A

The current formulation requires spirometry before initiation, at 6 months, and annually thereafter.

206
Q

Side effects of use of inhaled insulin aside from usual hypoglycemic risk

A

Cough or throat irritation

207
Q

TRUE or FALSE: Allergies to currently available insulins are common, as are chronic skin reactions, which include lipoatrophy and lipohypertrophy.

A

FALSE

Allergies to currently available insulins are rare, as are chronic skin reactions, which include lipoatrophy and lipohypertrophy.

208
Q

TRUE or FALSE: The onset and time to peak of insulins are similar regardless of dose.

A

FALSE

Both short-acting and long-acting insulins have profiles of action that vary by the size of the dose injected. With higher doses the onset and time to peak effect become more delayed and the total duration longer.

209
Q

First GLP1-based therapeutic agent to be approved for human use

A

Exenatide (synthetic exendin-4)

210
Q

Exendin-4 is a naturally occurring component of the saliva of the ___

A

Gila monster (Heloderma suspectum)

211
Q

TRUE or FALSE: Exendin-4 shares 53% sequences identity with GLP1 but is relatively resistant to degradation by DPP4.

A

TRUE

212
Q

Exenatide peak of action and total duration of action

A

Peak of action at about 2 hours
Total duration of action no more than 6 hours

Twice-daily injection before breakfast and dinner

213
Q

HbA1c reduction with use of exenatide

A

1%

214
Q

Weight loss with use of exenatide

A

Modest (2-4 kg)

215
Q

Most common adverse effect of exenatide

A

Nausea (50% of patients)

216
Q

GLP1 agonist that has properties similar to exenatide except for a slightly longer duration of action

A

Lixisenatide (once daily before breakfast; reduces postprandial increments of glucose during the daytime but has much less effect overnight)

217
Q

Long-acting GLP1 agonist that is administered once daily without any restriction as to timing or relation to meals

A

Liraglutide (the other long-acting agents are to be given once weekly)

218
Q

TRUE or FALSE: Long-acting GLP1 agonists are associated with greater HbA1c-lowering efficacy than short-acting agonists.

A

TRUE

Owing to their greater effects on overnight fasting glucose levels. Much less effect on postprandial increments of glucose than short-acting agents.

219
Q

What is the LEADER study?

A

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Randomized to treatment with liraglutide or placebo for a median of more than 3 years –> Significant reductions of risk for primary composite cardiovascular endpoint (CV death, nonfatal MI, or nonfatal stroke) (13%), CV death (22%), all-cause mortality (15%), and progression of albuminuria (26%). No significant effect on hospitalization for heart failure.

220
Q

What is SUSTAIN-6?

A

Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 DIabetes

Randomized to semaglutide vs placebo for about 2 years –> Somewhat greater reduction of risk for its primary cardiovascular composite endpoint (26%) compared with LEADER and showed a reduction in renal endpoints. Nonsignificant effect on CV death, all cause death, hospitalization for heart failure, and progression of albuminuria.

221
Q

Endpoint that didn’t show any improvement in both LEADER and SUSTAIN-6

A

Hospitalizations for heart failure (Up to now, these favorable outcomes have not been found with short-acting GLP1 agonists.)

222
Q

TRUE or FALSE: Hypoglycemia is a direct effect of GLP1 receptor agonists.

A

FALSE

Hypoglycemia is not a direct effect of GLP1 receptor agonists but can occur when they are added to other agents.

Hence, reduce to minimum dose of secretagogue, and 20% reduction of insulin dosage is advised unless HbA1c is >8%.

223
Q

The only GLP1 agonist that is renally cleared and is contraindicated in the setting of advanced kidney disease (eGFR <30)

A

Exenatide

224
Q

Contraindications for GLP1 agonists (4)

A

Type 1 diabetes
Diabetic ketoacidosis
History of pancreatitis
Personal or family history of medullary thyroid cancer (clear increase in preclinical testing with rodents)

225
Q

Side effects of GLP1 agonists

A

Nausea, diarrhea, abdominal pain
Pancreatitis?

226
Q

TRUE or FALSE: Most of the effect of pramlintide on glycemic pattern is a reduction of basal glucose levels.

A

FALSE

Most of the effect of pramlintide on glycemic pattern is a reduction of postprandial increments, with little effect on overnight control.

227
Q

HbA1c reduction with use of pramlintide

A

0.5 to 0.7%

228
Q

Most common adverse effect of pramlintide

A

Mild or moderate nausea, which wanes with continued therapy

229
Q

Timing of administration of oral medications that require rapid absorption for effectiveness if pramlintide is also being given

A

Either 1 hour before or 2 hours after injection of pramlintide

230
Q

Contraindication for pramlintide

A

Confirmed gastroparesis

231
Q

TRUE or FALSE: A deficiency of amylin is evident in patients with T1DM or T2DM.

A

TRUE

In parallel with insulin deficiency

232
Q

Mechanisms of pramlintide

A

Amylin and insulin have complementary actions in regulating plasma glucose. Amylin binds to brain nuclei and promotes satiety and reduces appetite. Through efferent neural pathways it mediates a decrease in the rate of gastric emptying and limits inappropriate glucagon secretion in a glucose-dependent fashion. By these means it regulates the rate of plasma glucose appearance from the GI tract and the liver.

233
Q

Largest pathophysiologic subgroup of diabetes

A

Latent autoimmune diabetes of adulthood

234
Q

Another term for Latent autoimmune diabetes of adulthood

A

Adult-onset type 1 diabetes

235
Q

Diabetes pathophysiologic subgroup that comprises up to 12% of patients with diabetes after age 20

A

Latent autoimmune diabetes of adulthood or Adult-onset type 1 diabetes

236
Q

TRUE or FALSE: Regarding Latent autoimmune diabetes of adulthood / Adult-onset type 1 diabetes:
a. Frequently are obese
b. May have other autoimmune disorders or a family history of these
c. Diagnosis requires detection of anti-glutamic acid decarboxylase antibodies or anti-islet cell antibodies
d. Can only be treated with insulin

A

a. FALSE. Frequently are not obese
b. TRUE
c. FALSE. Lack of antibodies does not exclude an autoimmune process
d. FALSE. Insulin has been considered the main therapy from the outset, but other therapies may be possible in those with slow progression.

237
Q

Leading causes of pancreatic diabetes (Type 3c diabetes)

A

Acute or chronic pancreatitis, pancreatectomy for cancer or pancreatitis, hemochromatosis, and cystic fibrosis

238
Q

TRUE or FALSE: Patients with pancreatic diabetes share a tendency to have significant deficiency of insulin secretion and prominent fasting hyperglycemia.

A

FALSE

Patients with pancreatic diabetes share a tendency to have significant deficiency of insulin secretion and prominent postprandial hyperglycemia.

Commonly need insulin at or relatively soon after diagnosis and quite frequently require both basal and prandial

239
Q

TRUE or FALSE: Patients with pancreatic diabetes have significant decreases in glucagon secretion and in the effects of incretin hormones.

A

TRUE

240
Q

TRUE or FALSE: Regarding maturity-onset diabetes of the young (MODY):
a. Proportion of newly diagnosed adults with one of these conditions is estimated to be between 1 and 2%
b. All have a strong family history consistent with autosomal dominant inheritance with high penetrance

A

a. TRUE
b. FALSE. A strong family history consistent with autosomal dominant inheritance with high penetrance is typical but not always present.

241
Q

Presentation of GCK-MODY

A

Presents typically in youth as mild fasting hyperglycemia that is not progressive and causes little or no tissue damage over time (deficiency of glucokinase –> altered glucose sensing in the beta cell)

242
Q

Importance of diagnosis of GCK-MODY

A

To avoid unnecessary treatment of the patient and other identified members of the family. Current evidence indicates that those with a GCK mutation will not develop chronic complications of diabetes, and treatment is not likely to render significant changes in glucose control.

243
Q

Most common form of monogenic diabetes

A

Hepatic nucleocyte factor-1A (HNF1A)

244
Q

Presentation of Hepatic nucleocyte factor-1A (HNF1A)

A

In adulthood with progressive hyperglycemia, more postprandial than fasting, that responds very well to sulfonylureas

Can be suspected when there is a prominent history of adult-onset but quite stable and slowly progressive diabetes on one side of the patient’s family, often in the absence of obesity

245
Q

Default choice for initial drug therapy in type 2 diabetes

A

Metformin

Used in combination with diet, exercise, and a DSMES program, can usually provide impressive lowering of glucose with essentially no risk of hypoglycemia. Initial use also has evidence for reducing CV risk

246
Q

What is the ORIGIN trial?

A

Outcome Reduction with an Initial Glargine Intervention trial

Showed effectiveness of combination therapy. Randomized into glargine as basal insulin with continuation of prior oral therapy, and use of oral therapies with insulin added only if necessary. Both regimens maintained HbA1c levels close to 6.5%. No differences in medical outcomes were observed other than more hypoglycemia and less progression from dysglycemia to overt diabetes in the group assigned to initial glargine therapy.

247
Q

Usual initial dose of basal insulin

A

Treatment can be started either with a fixed daily dose of 10 units or with a dose calculated as 0.1 to 0.2 units per kilogram body weight.

248
Q

Failure to maintain HbA1c close to __% despite use of a regimen that includes properly titrated basal insulin calls for attention to postprandial hyperglycemia.

A

7%

249
Q

After therapy of basal glucose has been optimized, the postprandial glucose excursion is highest after ___, and the highest postprandial glucose is after ___.

A

Breakfast
Dinner

250
Q

Recent studies suggest that adding a single injection of short-acting insulin (at the morning meal or at the largest meal) is just as effective as basal-bolus therapy and is less likely to cause weight gain or hypoglycemia. Aim for glucose prior to next meal (or at bedtime if the dose is prior to dinner) approaching __ mg/dL.

A

120 mg/dL

251
Q

When prandial insulin is added to basal insulin with continuation of one or more oral agents, optimal control often requires total daily insulin doses greater than __ unit per kilogram of body weight daily

A

1

252
Q

Fig. 35.6. Glucose-lowering medication in type 2 diabetes. Page 1400

A

*

253
Q

First-line therapy in type 2 diabetes

A

Metformin and comprehensive lifestyle (including weight management and physical activity)

*To avoid clinical inertia, reassess and modify treatment regularly (3-6 months)

254
Q

Additional treatment if patient has established ASCVD or CKD - ASCVD predominates

A

EITHER GLP-1 RA with proven CVD benefit OR SGLT2i with proven CVD benefit

liraglutide > semaglutide > exenatide ER
empagliflozin > canagliflozin

255
Q

Additional treatment if patient has established ASCVD or CKD - HF or CKD predominates

A

PREFERABLY SGLT2i OR GLP-1 RA

256
Q

Medications to avoid if patient has HF

A

TZD
Saxagliptin

257
Q

Additional treatment if patient has compelling need to minimize hypoglycemia

A

DPP-4i
GLP-1 RA
SGLT2i
TZD

258
Q

Additional treatment if patient has compelling need to minimize weight gain or promote weight loss

A

EITHER GLP-1 RA OR SGLT2i
(ADA 2022: PREFERABLY GLP-1 RA OR SGLT2i)

Later on.. preferably DPP4-i if not on GLP-1 RA

259
Q

Additional treatment if cost is a major issue

A

SU or TZD
(ADA 2022: Certain insulins, SU, TZD)

260
Q

As a general rule, patients diagnosed with HbA1c above 9% should seek a gradual improvement of control with HbA1c below 7% within 6 months, with continuation of at least metformin after that. – What is the rationale for this?

A

Aside from the risk of hypoglycemia from use of insulin by relatively inexperienced patients, there is potential for worsening of retinopathy or neuropathy accompanying overly rapid reduction of glucose.

261
Q

Risk of reapperance of hyperglycemia consistent with the diagnosis of T2DM in women with history of GDM

A

50-70% after 15 to 25 years, a risk that is increased 10 to 18-fold

262
Q

Risks of GDM

A

Complicated delivery
Neonatal complications
Children exposed to hyperglycemia in utero have increased risk of later obesity and/or T2DM

263
Q

Glucose targets during gestation

A

Fasting <95 mg/dL
1-hr postprandial <140 mg/dL
2-hr postprandial <120 mg/dL

264
Q

OHAs that are sometimes used in GDM instead of insulin, but there are concerns about their safety

A

Metformin
Glyburide

265
Q

Lifestyle interventions can provide a reduction of ___ to ___ % in progression to diabetes over a period of 3 to 5 years

A

30 to 60%

266
Q

Intervention with metformin in patients at high risk for T2DM was associated with a somewhat smaller reduction in progression to diabetes. It had LESS effect in the following patients:

A

Older than 60 years of age
BMI of <30 kg/m2
Fasting plasma glucose <100 mg/dL

267
Q

Metformin therapy brings little risk and offers SUBSTANTIAL benefit for some individuals, notably those:

A

Under age 60 years
BMI >35 kg/m2
Women with previous gestational diabetes

*Therefore on balance, consideration of metformin in patients who are at particularly high risk is recommended.

268
Q

Best candidates for preventive strategies (preventing type 2 diabetes)

A

Patients with prediabetes:
- HbA1c >5.7% and particularly >=6%
- FPG >=100 mg/dL and particularly >=110 mg/dL
- Impaired glucose tolerance

Williams: Disorders of Carbohydrates and Fat Metabolism (6 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions